Jerusalem, Israel, December 10, 2023
- Indication of neurodegeneration slow down following IPL344 treatment
Immunity Pharma, a clinical-stage neurology-focused biopharmaceutical company, today updated on biomarker data from its Phase 2a study with IPL344 in ALS. In a poster presented at the 34th international symposium on ALS and motor neuron disease (MND), December 6-8, 2023, in Basel, Switzerland, the company reported an observed numerical reduction in plasma neurofilament NfL concentrations following IPL344
...